Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.

Animals Antineoplastic Agents, Immunological / pharmacology Biomarkers CD8-Positive T-Lymphocytes / drug effects Disease Models, Animal Epigenesis, Genetic Humans Immunomodulation / drug effects Lymphocyte Activation Mice Mice, Knockout Molecular Targeted Therapy Neoplasms / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Receptors, CXCR3 / metabolism T-Lymphocyte Subsets / drug effects Tumor Microenvironment Xenograft Model Antitumor Assays
CD8(+) T cells CXCL10 CXCL9 CXCR3 PD-1 chemokine dendritic cells immune checkpoint immunotherapy

Journal

Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918

Informations de publication

Date de publication:
18 06 2019
Historique:
received: 08 05 2018
revised: 19 02 2019
accepted: 23 04 2019
pubmed: 18 5 2019
medline: 2 11 2019
entrez: 18 5 2019
Statut: ppublish

Résumé

Despite compelling rates of durable clinical responses to programmed cell death-1 (PD-1) blockade, advances are needed to extend these benefits to resistant tumors. We found that tumor-bearing mice deficient in the chemokine receptor CXCR3 responded poorly to anti-PD-1 treatment. CXCR3 and its ligand CXCL9 were critical for a productive CD8

Identifiants

DOI: 10.1016/j.immuni.2019.04.010 PMID: 31097342 PMC: PMC6527362
pubmed: 31097342
pii: S1074-7613(19)30190-6
doi: 10.1016/j.immuni.2019.04.010
pmc: PMC6527362
mid: NIHMS1528323
pii:
doi:

Substances chimiques

Antineoplastic Agents, Immunological 0
Biomarkers 0
Programmed Cell Death 1 Receptor 0
Receptors, CXCR3 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1498-1512.e5

Subventions

Organisme : NCI NIH HHS
ID : R01 CA204028
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK043351
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA163222
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA222871
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR043369
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
J Exp Med. 2001 Apr 16;193(8):975-80
pubmed: 11304558
Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14759-64
pubmed: 17804806
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Oncotarget. 2015 Sep 22;6(28):24978-89
pubmed: 26317795
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Immunity. 2000 May;12(5):483-94
pubmed: 10843381
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Cancer Discov. 2016 Jan;6(1):71-9
pubmed: 26493961
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Gastroenterology. 2010 Apr;138(4):1429-40
pubmed: 19909745
Nat Med. 2014 Nov;20(11):1301-9
pubmed: 25344738
Immunity. 2017 Nov 21;47(5):848-861.e5
pubmed: 29126798
J Exp Med. 2000 Nov 20;192(10):1515-20
pubmed: 11085753
Annu Rev Med. 2018 Jan 29;69:301-318
pubmed: 29414259
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
J Exp Med. 1993 Sep 1;178(3):1057-65
pubmed: 8350046
Immunity. 2013 Mar 21;38(3):502-13
pubmed: 23352234
Cell. 2012 Sep 14;150(6):1249-63
pubmed: 22980984
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Nature. 2014 Nov 27;515(7528):572-6
pubmed: 25428506
Nature. 2012 Jun 28;486(7404):545-8
pubmed: 22722867
Gut. 2012 Mar;61(3):427-38
pubmed: 21930732
J Immunol. 2003 Dec 15;171(12):6838-45
pubmed: 14662890
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
Immunol Cell Biol. 2011 Feb;89(2):207-15
pubmed: 21221121
Exp Cell Res. 2011 Mar 10;317(5):620-31
pubmed: 21376175
Immunity. 2016 Oct 18;45(4):719-736
pubmed: 27760337
Immunity. 2015 Mar 17;42(3):524-37
pubmed: 25769612
Nature. 2015 Nov 12;527(7577):249-53
pubmed: 26503055
Sci Transl Med. 2014 Feb 12;6(223):223ra23
pubmed: 24523323
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
Clin Cancer Res. 2015 Nov 15;21(22):5047-56
pubmed: 26567364
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Cancer Cell. 2018 Jan 8;33(1):60-74.e6
pubmed: 29316433
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
Nat Commun. 2015 Jun 25;6:7458
pubmed: 26109379
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7240-E7249
pubmed: 27799536
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
J Immunol. 2002 Aug 1;169(3):1433-43
pubmed: 12133969
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Sci Rep. 2012;2:765
pubmed: 23097687
J Pathol. 2011 Feb;223(3):347-57
pubmed: 21171080
Nature. 2004 Jan 22;427(6972):355-60
pubmed: 14737169
Cell. 2017 Jan 26;168(3):487-502.e15
pubmed: 28111070
Immunity. 2012 Dec 14;37(6):1091-103
pubmed: 23123063
Nat Rev Immunol. 2016 Oct;16(10):599-611
pubmed: 27526640
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
J Immunother Cancer. 2014 Feb 18;2:3
pubmed: 24829760
J Immunol. 2002 Apr 1;168(7):3195-204
pubmed: 11907072
Cancer Res. 2011 Aug 15;71(16):5455-66
pubmed: 21715565
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023
J Exp Med. 2017 Apr 3;214(4):895-904
pubmed: 28302645

Auteurs

Melvyn T Chow (MT)

Center for Immunology & Inflammatory Diseases, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Aleksandra J Ozga (AJ)

Center for Immunology & Inflammatory Diseases, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Rachel L Servis (RL)

Center for Immunology & Inflammatory Diseases, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Dennie T Frederick (DT)

Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Jennifer A Lo (JA)

Cutaneous Biology Research Center, Department of Dermatology and MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

David E Fisher (DE)

Cutaneous Biology Research Center, Department of Dermatology and MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Gordon J Freeman (GJ)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Genevieve M Boland (GM)

Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Andrew D Luster (AD)

Center for Immunology & Inflammatory Diseases, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: aluster@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunomodulation › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Phénomènes du système immunitaire › Activation des lymphocytes › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Souris knockout › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Thérapie moléculaire ciblée › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Tumeurs › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Récepteur-1 de mort cellulaire programmée › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs aux cytokines › Récepteurs aux chimiokines › Récepteurs CXCR › Récepteurs CXCR3 › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Intratumoral Activity of the CXCR3 Chemokine...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Intratumoral Activity of the CXCR3 Chemokine...